Next Article in Journal
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Previous Article in Journal
Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer
Previous Article in Special Issue
Association of miR-34a Expression with Quality of Life of Glioblastoma Patients: A Prospective Study
Article Menu

Export Article

Open AccessBrief Report
Cancers 2019, 11(3), 365; https://doi.org/10.3390/cancers11030365

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

1
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
2
Department of Respiratory Medicine Uji-Tokushukai Medical Center, Kyoto 611-0041, Japan
3
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan
4
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan
5
Department of Respiratory Medicine, Otsu City Hospital, Otsu 520-0804, Japan
*
Author to whom correspondence should be addressed.
Received: 20 February 2019 / Revised: 10 March 2019 / Accepted: 13 March 2019 / Published: 15 March 2019
(This article belongs to the Collection Cancer Biomarkers)
Full-Text   |   PDF [1145 KB, uploaded 15 March 2019]   |  
  |   Review Reports

Abstract

Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the factors affecting response to osimertinib treatment are unknown. In this retrospective study, 27 NSCLC patients with the EGFR-T790M mutation were enrolled at five institutions in Japan. Among several parameters tested, the progression-free survival (PFS) associated with the initial EGFR-TKIs was positively correlated with the PFS after osimertinib treatment (p = 0.021). The median PFS following osimertinib treatment and the overall survival (OS) were longer in patients who responded to osimertinib than in those who did not (17.7 months versus 3.5 months, p = 0.009 and 24.2 months versus 13.5 months, p = 0.021, respectively). A multivariate analysis demonstrated that the PFS with initial EGFR-TKIs was significantly related to the PFS with osimertinib treatment (p = 0.035), whereas osimertinib response was significantly related to the PFS and OS with osimertinib treatment (p = 0.016 and p = 0.006, respectively). Our retrospective observations indicate that PFS following the initial EGFR-TKI treatment and the response rate to osimertinib might be promising predictors for effective osimertinib treatment in NSCLC patients with the EGFR-T790M mutation. View Full-Text
Keywords: osimertinib; EGFR-T790M mutation; non-small cell lung cancer; biomarker; retrospective study osimertinib; EGFR-T790M mutation; non-small cell lung cancer; biomarker; retrospective study
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Yoshimura, A.; Yamada, T.; Okura, N.; Takeda, T.; Hirose, K.; Kubota, Y.; Shiotsu, S.; Hiranuma, O.; Chihara, Y.; Tamiya, N.; Kaneko, Y.; Uchino, J.; Takayama, K. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers 2019, 11, 365.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top